253307-65-2
253307-65-2
Chemical Structure
PBR28
- CAS No.: 253307-65-2
- Formula:C21H20N2O3
- Molecular Weight:348.40
IUPAC Name: N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide
InChIKey: DHZBNHMEIOBPAE-UHFFFAOYSA-N
SMILES: O=C(C)N(CC1=C(OC)C=CC=C1)C2=C(OC3=CC=CC=C3)C=CN=C2
Biological Activity: PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability[1][2]. PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PBR28 | 98.91% | PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability. PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ly93 | 99.85% | Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DAA-1097 | DAA-1097 is an orally active and selective agonist for the peripheral benzodiazepine receptor (PBR). DAA-1097 has anxiolytic effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AOH1160 | 98.56% | AOH1160 is a potent oral small molecule proliferating cell nuclear antigen (PCNA) inhibitor that interferes with DNA replication, blocks homologous recombination-mediated DNA repair, leads to cell cycle arrest and induces apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acetobixan | Acetobixan is an inhibitor of Cellulose Synthase A6 (CESA6). Acetobixan inhibits cellulose components of Pythium insidiosum cell walls. Acetobixan can be used for the research of Pythium insidiosum keratitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MERS-CoV-IN-1 | 99.53% | MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BPK-21 | 99.63% | BPK-21, an active acrylamide, suppresses T cell activation through blockade of ERCC3 function. BPK-21 specifically targets C342 in the helicase ERCC3. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CCW16 | 98.73% | CCW16 is a non-selective cysteine-reactive covalent ligand and an RNF4 E3 ubiquitin ligase recruiter with an IC50 of 1.8 μM against human RNF4[. CCW16 covalently modifies accessible cysteine residues on RNF4, PRDX1, PRDX2, and PRDX6, attenuating the peroxide-scavenging activity of peroxiredoxins. CCW16 induces oxidative stress through upregulation of HMOX1 and NRF2, and triggers ferroptosis via lipid peroxidation and ROS signaling pathways in an RNF4-independent manner. CCW16 serves as an RNF4-recruiting moiety; it does not induce RNF4 degradation when used alone and can be used to synthesize protein degraders, such as the PROTAC compound CCW 28-3 (HY-156774). CCW16 can be used for research on acute myeloid leukemia and hepatocellular carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AChE-IN-26 | 99.73% | AChE-IN-26 (compound 4a) is an AChE (acetylcholinesterase) inhibitor with an IC50 value of 0.42 μM. AChE-IN-26 can be used for the research of Alzheimer’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-HT/NA Reuptake inhibitor-1 | 5-HT/NA Reuptake inhibitor-1 (compound 9) is a selective dual 5-HT and NA reuptake inhibitor with IC50 of 660 nM and 70 nM respectively. . 5-HT/NA Reuptake inhibitor-1 has good in vitro human metabolic stability, hERG selectivity and passive membrane permeability. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DAA-1106 (Standard) | ≥98% | DAA-1106 (Standard) is the analytical standard of DAA-1106. This product is intended for research and analytical applications. 0 | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sander CY, et al. [11C]PBR28 radiotracer kinetics are not driven by alterations in cerebral blood flow. J Cereb Blood Flow Metab. 2021;41(11):3069-3084. [Content Brief]
- [2]. Boerwinkle AH, et al. Comparison of [11C]-PBR28 Binding Between Persons Living With HIV and HIV-Uninfected Individuals. J Acquir Immune Defic Syndr. 2020;85(2):244-251. [Content Brief]
